• Disclosure
  • Privacy Policy
  • DMCA Policy
  • CCPA
  • Medical Disclaimer
Tuesday, March 21, 2023
SLC Online News
  • Home
  • News
  • Business
  • Technology
    • Crytpocurrency
    • Gaming
    • Gadgets
  • Sports
  • Health
  • General
    • Business Services
  • Travel
  • Press Releases
  • Popular
No Result
View All Result
  • Home
  • News
  • Business
  • Technology
    • Crytpocurrency
    • Gaming
    • Gadgets
  • Sports
  • Health
  • General
    • Business Services
  • Travel
  • Press Releases
  • Popular
No Result
View All Result
No Result
View All Result
Home News

U.S. FDA Backs Pfizer’s COVID-19 Booster Shot For 12- To 15-Year-Olds – Reuters

us.-fda-backs-pfizer’s-covid-19-booster-shot-for-12-to-15-year-olds-–-reuters
Share on FacebookShare on Twitter

Brendan Lo (13) receives a dose of the Pfizer-BioNTech vaccine for the coronavirus disease (COVID-19) at Northwell Health’s Cohen Children’s Medical Center in New Hyde Park, New York, U.S., May 13, 2021. REUTERS/Shannon Stapleton

Register now for FREE unlimited access to Reuters.com

WASHINGTON, Jan 3 (Reuters) – The U.S. Food and Drug Administration on Monday authorized the use of a third dose of the Pfizer (PFE.N) and BioNTech COVID-19 vaccine for children ages 12 to 15, and narrowed the time for all booster shots by a month to five months after the primary doses.

The agency also authorized a third shot for children aged 5 through 11 years who are immunocompromised.

The regulatory decisions come as schools reopen in much of the country, and as COVID-19 cases surge due to the Omicron variant of the virus, with health authorities warning that its high transmissibility could overwhelm many health systems.

Register now for FREE unlimited access to Reuters.com

The U.S. Centers for Disease Control and Prevention is expected to weigh in on the changes this week, according to the New York Times. The CDC was not immediately available for comment.

“Based on the FDA’s assessment of currently available data, a booster dose of the currently authorized vaccines may help provide better protection against both the Delta and Omicron variants,” said Peter Marks, director of the FDA’s Center for Biologics Evaluation and Research.

The U.S. government has been urging vaccinated Americans to get boosters and for the unvaccinated, who are at much higher risk of severe COVID-19 and death, to be inoculated.

So far, 62% of the eligible U.S. population is considered fully vaccinated with a third of them also having received a booster dose.

In making its decision, the FDA said it reviewed real-world data from Israel, including safety data from more than 6,300 individuals aged 12 through 15 years who received a booster dose of the Pfizer-BioNTech vaccine at least 5 months following completion of the primary two-dose vaccination series.

There were no new cases of a rare type of heart inflammation reported to-date in these individuals, the FDA said.

Laboratory tests have shown that two doses of the Pfizer-BioNTech and Moderna (MRNA.O) vaccines generate low immune responses against Omicron, while the addition of a booster appears to restore protection against the highly-mutated variant.

Two shots of the mRNA vaccine are about 35% effective against infection from the Omicron variant, but a booster dose restores effectiveness to 75%, according to the CDC, based on data from South Africa and the United Kingdom.

The FDA said authorizing the shot at 5 months instead of 6 may provide better protection sooner against Omicron.

Dr. Eric Topol, director of the Scripps Research Translational Institute in La Jolla, California, said a third shot is essential to protect against Omicron for severe disease.

“A good thing here is also the change on the timing of the booster to five months instead of six. That’s a big step for this country, which has been resistant to the data,” he added.

Countries including the United Kingdom and Israel have narrowed their window for boosters from six months to three or four following the second shot to try to fight the spread of the easily transmitted Omicron variant.

Amesh Adalja, a senior scholar at the Johns Hopkins Institute for Health Security, said he does not believe a boosters is necessary for most people since two doses of the vaccine have been effective at preventing hospitalizations and severe disease in all but older people.

“When I work at the hospital, I don’t see patients there because they lack a booster, I see patients because they lack first and second doses,” Adalja said.

Register now for FREE unlimited access to Reuters.com

Reporting by Ankur Banerjee and Manas Mishra in Bengaluru and Ahmed Aboulenein in Washington DC; Editing by Sriraj Kalluvila and Bill Berkrot

Our Standards: The Thomson Reuters Trust Principles.

SLC Online News

© 2021 SLC Online News

Navigate Site

  • Disclosure
  • Privacy Policy
  • DMCA Policy
  • CCPA
  • Medical Disclaimer

Follow Us

No Result
View All Result
  • Home
  • DMCA Policy
  • Medical Disclaimer
  • Privacy Policy
  • Disclosure
  • CCPA
  • Terms of Use

© 2021 SLC Online News

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept All”, you consent to the use of ALL the cookies. However, you may visit "Cookie Settings" to provide a controlled consent.
Cookie SettingsAccept All
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT